統合失調症（Schizophrenia）：グローバル医薬品市場動向（～2022）...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 9
1.1 List of Tables 16
1.2 List of Figures 21
2 Introduction 22
2.1 Catalyst 22
2.2 Upcoming Reports 22
3 Disease Overview 23
3.1 Etiology and Pathophysiology 23
3.1.1 Etiology 23
3.1.2 Pathophysiology 24
3.2 Symptoms 25
4 Epidemiology 26
4.1 Disease Background 26
4.2 Risk Factors and Comorbidities 27
4.2.1 Psychiatric illness in first-degree relatives is a strong predictor of schizophrenia 28
4.2.2 Advancing paternal age increases the risk of schizophrenia in offspring 29
4.2.3 Psychiatric comorbidities are common in patients with schizophrenia 30
4.2.4 People with schizophrenia suffer from several medical comorbidities 31
4.3 Global Trends 34
4.3.1 US 37
4.3.2 5EU 38
4.3.3 Japan 41
4.4 Forecast Methodology 42
4.4.1 Sources Used 42
4.4.2 Sources Not Used 45
4.4.3 Forecast Assumptions and Methods, Prevalent Cases 45
4.5 Epidemiological Forecast of Schizophrenia (2012-2022) 47
4.5.1 Diagnosed Prevalent Cases of Schizophrenia 47
4.5.2 Age-Specific Prevalent Cases of Schizophrenia 49
4.5.3 Sex-Specific Prevalent Cases of Schizophrenia 51
4.5.4 Age-Standardized Diagnosed Prevalence of Schizophrenia 53
4.6 Discussion 54
4.6.1 Epidemiological Forecast Insight 54
4.6.2 Limitations of the Analysis 55
4.6.3 Strengths of the Analysis 56
5 Disease Management 57
5.1 Diagnosis 57
5.1.1 Subjective Assessments 58
5.1.2 Disease Subtypes 59
5.2 Treatment Overview 62
5.2.1 Treatment of Acute Agitation Associated with Schizophrenia 64
5.2.2 Maintenance Treatment of Schizophrenia 65
5.3 US 66
5.3.1 Diagnosis 66
5.3.2 Clinical Practice 66
5.4 France 67
5.4.1 Diagnosis 67
5.4.2 Clinical Practice 68
5.5 Germany 69
5.5.1 Diagnosis 69
5.5.2 Clinical Practice 69
5.6 Italy 71
5.6.1 Diagnosis 71
5.6.2 Clinical Practice 71
5.7 Spain 72
5.7.1 Diagnosis 72
5.7.2 Clinical Practice 72
5.8 UK 73
5.8.1 Diagnosis 73
5.8.2 Clinical Practice 74
5.9 Japan 75
5.9.1 Diagnosis 75
5.9.2 Clinical Practice 75
6 Competitive Assessment 77
6.1 Overview 77
6.2 Strategic Competitor Assessment 78
6.3 Product Profiles by Generation 79
6.3.1 Conventional Antipsychotics 79
6.3.2 Atypical Antipsychotics 83
7 Opportunity and Unmet Need 120
7.1 Unmet Needs Overview 120
7.1.1 Public Awareness 121
7.1.2 Early Diagnosis and Treatment 123
7.1.3 Long-Acting and Advanced Drug Delivery Systems 124
7.1.4 Effective Management of Negative and Cognitive Symptom Domains 125
7.2 Gap Analysis 126
7.2.1 Long-Acting Drug Delivery 127
7.2.2 Treatment of Negative and Cognitive Symptoms 127
8 Pipeline Assessment 128
8.1 Overview 128
8.2 Clinical Trial Mapping 129
8.2.1 Clinical Trials by Country 129
8.2.2 Clinical Trials by Phase and Trial Status 130
8.3 Early-Stage Pipeline Assessment 131
8.4 Novel Therapeutic Approaches 132
8.4.1 Negative Symptoms 132
8.4.2 Cognitive Symptoms 132
8.5 Long-Acting Drug Delivery 133
8.6 Technology Trends Analysis 133
8.7 Key Drugs in Clinical Development 134
8.7.1 Aripiprazole Lauroxil 136
8.7.2 Cariprazine 141
8.7.3 Brexpiprazole 145
8.7.4 Zicronapine 149
8.7.5 Bitopertin 152
8.7.6 EVP-6124 156
9 Current and Future Players 160
9.1 Overview 160
9.2 Trends in Corporate Strategy 161
9.3 Company Profiles 161
9.3.1 Janssen Pharmaceuticals 161
9.3.2 Eli Lilly and Company 164
9.3.3 Roche 166
9.3.4 Alkermes 168
9.3.5 EnVivo Pharmaceuticals 170
10 Market Outlook 172
10.1 Global Markets 172
10.1.1 Forecast 172
10.1.2 Global Drivers and Barriers 176
10.2 US 177
10.2.1 Forecast 177
10.2.2 Key Events 181
10.2.3 Drivers and Barriers 181
10.3 France 184
10.3.1 Forecast 184
10.3.2 Key Events 187
10.3.3 Drivers and Barriers 187
10.4 Germany 189
10.4.1 Forecast 189
10.4.2 Key Events 193
10.4.3 Drivers and Barriers 193
10.5 Italy 195
10.5.1 Forecast 195
10.5.2 Key Events 198
10.5.3 Drivers and Barriers 199
10.6 Spain 201
10.6.1 Forecast 201
10.6.2 Key Events 204
10.6.3 Drivers and Barriers 204
10.7 UK 205
10.7.1 Forecast 205
10.7.2 Key Events 208
10.7.3 Drivers and Barriers 208
10.8 Japan 210
10.8.1 Forecast 210
10.8.2 Key Events 213
10.8.3 Drivers and Barriers 213
11 Appendix 216
11.1 Bibliography 216
11.2 Abbreviations 231
11.3 Methodology 236
11.4 Forecasting Methodology 236
11.4.1 Diagnosis and Treatment Rates 236
11.4.2 Adherence Rates 237
11.4.3 Drugs Included in Each Therapeutic Class 237
11.4.4 Launch and Patent Expiry Dates 238
11.4.5 General Pricing Assumptions 239
11.4.6 Drug Assumptions 240
11.4.7 Generic Erosion 247
11.4.8 Pricing of Pipeline Agents 247
11.5 Key Opinion Leaders 249
11.6 About the Authors 250
11.6.1 Author 250
11.6.2 Epidemiology 250
11.6.3 Reviewers 251
11.6.4 Global Head of Healthcare 251
11.7 About GlobalData 252
11.8 Disclaimer 252